RxDoctor Payments Data

Kara Cizdziel, MD

Family Medicine · Dallas, TXNPI 1558507913

Payments from drug & device makers

$445in general payments, 2019–2025

Across 25 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$170
  • Gilead$51
  • Corcept Therapeutics$43
  • AbbVie$41
  • Novo Nordisk$32
  • AstraZeneca$18
  • plus $89 from 6 others

What the payments were for

  • Food & beverage$445100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$445 in reported general payments places this provider in the 45th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$180
Medicare patients
25
Services billed
32

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$57,644
FarxigaDapagliflozin Propanediol49$52,182
MounjaroTirzepatide27$31,326
TrulicityDulaglutide28$31,285
JardianceEmpagliflozin15$26,905
EliquisApixaban31$26,349
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$22,550
JanuviaSitagliptin Phosphate20$22,057
VraylarCariprazine Hcl12$17,454
MyrbetriqMirabegron28$13,135
LinzessLinaclotide12$7,931
SymbicortBudesonide/Formoterol Fumarate16$5,085
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$4,681
Duloxetine Hcl131$4,359
LantusInsulin Glargine,hum.Rec.Anlog17$3,422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$18$79,81692 claims
Novo NordiskOzempic$32$57,64449 claims
Boehringer IngelheimJardiance$17$26,90515 claims
PfizerEliquis$18$26,34931 claims
AbbVieVraylar, Linzess$41$25,38524 claims
MerckJanuvia$13$22,05720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →